NCT00888810 - Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Conditions

CancerOvarianRelapseChemotherapy

Interventions

DRUG

TOPOTECAN

IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)

DRUG

LAPATINIB

Daily oral administration during all the study. 1250 mg/day

Trial Locations (21)

14076

Centre François Baclesse, Caen

21076

Centre G-F Leclerc, Dijon

25030

CHU Jean MINJOZ, Besançon

31052

Institut Claudius regaud, Toulouse

33076

Institut Bergonié, Bordeaux

34298

Centre Val d'Aurelle, Montpellier

42271

Institut de Cancérologie de la Loire, Saint-Etienne

44202

Centre Catherine de Sienne, Nantes

44805

Centre René Gauducheau, Nantes

49933

Centre Paul Papin, Angers

51056

Institut Jean Godinot, Reims

54511

Centre Alexis vautrin, Nancy

67065

Centre Paul Strauss, Strasbourg

72015

Centre Jean Bernard, Le Mans

75012

Hôpital Diaconesses, Paris

75231

Institut CURIE, Paris

75970

APHP Hopital TENON, Paris

85025

CHD Les Oudairies, La Roche-sur-Yon

94805

Institut Gustave Roussy, Villejuif

06250

Centre azuréen de cancérologie, Mougins

06189

Centre Antoine Lacassagne, Nice